These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 18433583

  • 1. [Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark].
    Palmer AJ, Lammert M, Hermansen K.
    Ugeskr Laeger; 2008 Apr 07; 170(15):1250-4. PubMed ID: 18433583
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries.
    Gschwend MH, Aagren M, Valentine WJ.
    J Med Econ; 2009 Jun 07; 12(2):114-23. PubMed ID: 19545216
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ.
    Adv Ther; 2008 Aug 07; 25(8):752-74. PubMed ID: 18704282
    [Abstract] [Full Text] [Related]

  • 4. Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy.
    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Nicklasson L, Spinas GA.
    Curr Med Res Opin; 2004 Aug 07; 20 Suppl 1():S67-73. PubMed ID: 15324518
    [Abstract] [Full Text] [Related]

  • 5. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
    Ali M, White J, Lee CH, Palmer JL, Smith-Palmer J, Fakhoury W, Valentine WJ.
    J Med Econ; 2008 Aug 07; 11(4):651-70. PubMed ID: 19450074
    [Abstract] [Full Text] [Related]

  • 6. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.
    Valentine WJ, Jendle J, Saraheimo M, Thorsteinsson B, Pollock RF, Lammert M.
    Diabet Med; 2012 Mar 07; 29(3):303-12. PubMed ID: 21951030
    [Abstract] [Full Text] [Related]

  • 7. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T.
    Dtsch Med Wochenschr; 2009 Jun 07; 134(23):1207-13. PubMed ID: 19472091
    [Abstract] [Full Text] [Related]

  • 8. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
    Levin P.
    Diabetes Obes Metab; 2008 Jul 07; 10 Suppl 2():66-75. PubMed ID: 18577158
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden.
    Valentine WJ, Aagren M, Haglund M, Ericsson A, Gschwend MH.
    Scand J Public Health; 2011 Feb 07; 39(1):79-87. PubMed ID: 20688795
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study.
    Almbrand B, Johannesson M, Sjöstrand B, Malmberg K, Rydén L.
    Eur Heart J; 2000 May 07; 21(9):733-9. PubMed ID: 10739728
    [Abstract] [Full Text] [Related]

  • 11. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B, Rodby RA.
    Nephrol Dial Transplant; 2008 Apr 07; 23(4):1216-23. PubMed ID: 18359872
    [Abstract] [Full Text] [Related]

  • 12. Direct healthcare costs of patients with type 2 diabetes using long-acting insulin analogues or NPH insulin in a basal insulin-only regimen.
    Gundgaard J, Christensen TE, Thomsen TL.
    Prim Care Diabetes; 2010 Oct 07; 4(3):165-72. PubMed ID: 20452847
    [Abstract] [Full Text] [Related]

  • 13. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O, Breitscheidel L, Benter U, Dippel FW, Müller M, Volk M, Pfohl M.
    J Med Econ; 2008 Oct 07; 11(4):695-712. PubMed ID: 19450076
    [Abstract] [Full Text] [Related]

  • 14. Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting.
    Roze S, Valentine WJ, Evers T, Palmer AJ.
    Curr Med Res Opin; 2006 Jul 07; 22(7):1415-24. PubMed ID: 16834840
    [Abstract] [Full Text] [Related]

  • 15. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K, Dornhorst A, Sreenan S.
    Curr Med Res Opin; 2009 Nov 07; 25(11):2601-8. PubMed ID: 19739940
    [Abstract] [Full Text] [Related]

  • 16. Technology and the issue of cost/benefit in diabetes.
    Giannini C, Mohn A, Chiarelli F.
    Diabetes Metab Res Rev; 2009 Sep 07; 25 Suppl 1():S34-44. PubMed ID: 19662616
    [Abstract] [Full Text] [Related]

  • 17. Premixed insulin treatment for type 2 diabetes: analogue or human?
    Garber AJ, Ligthelm R, Christiansen JS, Liebl A.
    Diabetes Obes Metab; 2007 Sep 07; 9(5):630-9. PubMed ID: 17697056
    [Abstract] [Full Text] [Related]

  • 18. [Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM study].
    von Ferber L, Köster I, Hauner H.
    Med Klin (Munich); 2006 May 15; 101(5):384-93. PubMed ID: 16685485
    [Abstract] [Full Text] [Related]

  • 19. Healthcare costs of fast-acting insulin analogues versus short-acting human insulin for Danish patients with type 2 diabetes on a basal-bolus regimen.
    Christensen TE, Gundgaard J, Pilgaard T.
    J Med Econ; 2011 May 15; 14(4):477-85. PubMed ID: 21668290
    [Abstract] [Full Text] [Related]

  • 20. Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany.
    Pfohl M, Schädlich PK, Dippel FW, Koltermann KC.
    J Med Econ; 2012 May 15; 15 Suppl 2():14-27. PubMed ID: 22812690
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.